A Potential Prognostic Gene Signature Associated with p53-Dependent NTRK1 Activation and Increased Survival of Neuroblastoma Patients
Authors:
- David CurrieDCDavid Currie
- Nicole WongNWNicole Wong
- Isabelle ZaneIZIsabelle Zane
- Tom RixTRTom Rix
- Marios VardakastanisMVMarios Vardakastanis
- Amelia ClaxtonACAmelia Claxton
- Karine K. V. OngKOKarine K. V. Ong
- William MacmorlandWMWilliam Macmorland
- Arthur PoivetAPArthur Poivet
- Anthony BrooksABAnthony Brooks
- Paola NiolaPNPaola Niola
- Derek HuntleyDHDerek Huntley
Open Access
Abstract
Neuroblastoma is the most common extracranial solid tumour in children, comprising close to 10% of childhood cancer-related deaths. We have demonstrated that activation of NTRK1 by TP53 repression of PTPN6 expression is significantly associated with favourable survival in neuroblastoma. The molecular mechanisms by which this activation elicits cell molecular changes need to be determined. This is critical to identify dependable biomarkers for the early detection and prognosis of tumours, and for the development of personalised treatment. In this investigation we have identified and validated a gene signature for the prognosis of neuroblastoma using genes differentially expressed upon activation of the NTRK1-PTPN6-TP53 module. A random survival forest model was used to construct a gene signature, which was then assessed across validation datasets using Kaplan–Meier analysis and ROC curves. The analysis demonstrated that high BASP1, CD9, DLG2, FNBP1, FRMD3, IL11RA, ISGF10, IQCE, KCNQ3, and TOX2, and low BSG/CD147, CCDC125, GABRB3, GNB2L1/RACK1 HAPLN4, HEBP2, and HSD17B12 expression was significantly associated with favourable patient event-free survival (EFS). The gene signature was associated with favourable tumour histology and NTRK1-PTPN6-TP53 module activation. Importantly, all genes were significantly associated with favourable EFS in an independent manner. Six of the signature genes, BSG/CD147, GNB2L1/RACK1, TXNDC5, FNPB1, B3GAT1, and IGSF10, play a role in cell differentiation. Our findings strongly suggest that the identified gene signature is a potential prognostic biomarker and therapeutic target for neuroblastoma patients and that it is associated with neuroblastoma cell differentiation through the activation of the NTRK1-PTPN6-TP53 module.Keywords
Funding Information
- Rosetrees Trust (M159-F2)
This publication has 88 references indexed in Scilit:
- Effect of p53 and its N‐terminally truncated isoform, Δ40p53, on breast cancer migration and invasionMolecular Oncology, 2021
- High FRMD3 expression is prognostic for worse survival in rectal cancer patients treated with CCRTInternational Journal of Clinical Oncology, 2021
- Expression of immune checkpoints and T cell exhaustion markers in early and advanced stages of colorectal cancerCancer Immunology, Immunotherapy, 2020
- NovelIQCEvariations confirm its role in postaxial polydactyly and cause ciliary defect phenotype in zebrafishHuman Mutation, 2019
- Impact of 17β-HSD12, the 3-ketoacyl-CoA reductase of long-chain fatty acid synthesis, on breast cancer cell proliferation and migrationCellular and Molecular Life Sciences, 2019
- Effect of cell source and osteoblast differentiation on gene expression profiles of mesenchymal stem cells derived from bone marrow or adipose tissueJournal of Cellular Biochemistry, 2019
- A review of neuroblastoma image-defined risk factors on magnetic resonance imagingPediatric Radiology, 2018
- Deregulated ALG‐2/HEBP2 axis alters microtubule dynamics and mitotic spindle behavior to stimulate cancer developmentJournal of Cellular Physiology, 2016
- Clinical significance of NTRK family gene expression in neuroblastomasPediatric Blood & Cancer, 2011
- Cloning and Chromosomal Mapping of Human Glucuronyltransferase Involved in Biosynthesis of the HNK-1 Carbohydrate EpitopeGenomics, 2000